HUP9901562A3 - Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system - Google Patents

Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Info

Publication number
HUP9901562A3
HUP9901562A3 HU9901562A HUP9901562A HUP9901562A3 HU P9901562 A3 HUP9901562 A3 HU P9901562A3 HU 9901562 A HU9901562 A HU 9901562A HU P9901562 A HUP9901562 A HU P9901562A HU P9901562 A3 HUP9901562 A3 HU P9901562A3
Authority
HU
Hungary
Prior art keywords
antibody
cea
conjugates
therapeutic use
monoclonal antibody
Prior art date
Application number
HU9901562A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP9901562A2 publication Critical patent/HUP9901562A2/hu
Publication of HUP9901562A3 publication Critical patent/HUP9901562A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
HU9901562A 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system HUP9901562A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein

Publications (2)

Publication Number Publication Date
HUP9901562A2 HUP9901562A2 (hu) 1999-08-30
HUP9901562A3 true HUP9901562A3 (en) 2000-06-28

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901562A HUP9901562A3 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Country Status (19)

Country Link
US (2) US6277599B1 (cg-RX-API-DMAC10.html)
EP (1) EP0896626B1 (cg-RX-API-DMAC10.html)
JP (1) JP2000510692A (cg-RX-API-DMAC10.html)
CN (1) CN1217750A (cg-RX-API-DMAC10.html)
AT (1) ATE350478T1 (cg-RX-API-DMAC10.html)
AU (1) AU719513B2 (cg-RX-API-DMAC10.html)
BR (1) BR9708910A (cg-RX-API-DMAC10.html)
CA (1) CA2250579A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ353698A3 (cg-RX-API-DMAC10.html)
DE (1) DE69737188T2 (cg-RX-API-DMAC10.html)
ES (1) ES2279539T3 (cg-RX-API-DMAC10.html)
HU (1) HUP9901562A3 (cg-RX-API-DMAC10.html)
IL (1) IL126772A0 (cg-RX-API-DMAC10.html)
NO (1) NO985120L (cg-RX-API-DMAC10.html)
NZ (1) NZ331978A (cg-RX-API-DMAC10.html)
PL (1) PL329871A1 (cg-RX-API-DMAC10.html)
SK (1) SK150298A3 (cg-RX-API-DMAC10.html)
TR (1) TR199802227T2 (cg-RX-API-DMAC10.html)
WO (1) WO1997042329A1 (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708910A (pt) * 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
WO1998035988A1 (en) * 1997-02-14 1998-08-20 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2321947A1 (en) * 1998-02-25 1999-09-02 The Dow Chemical Company High affinity humanized anti-cea monoclonal antibodies
EP1131428A2 (en) * 1998-11-19 2001-09-12 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
WO2000037615A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Recombinant synthesis of beta-lipotropin and other peptides
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
WO2001080880A2 (de) * 2000-04-22 2001-11-01 Stefan Barth Apoptotika
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
EP1606387A4 (en) * 2003-03-04 2008-04-23 Alexion Pharma Inc VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS
EP2404615A1 (en) * 2003-04-23 2012-01-11 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int MOLECULES CAB
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
WO2005111078A2 (en) * 2004-04-15 2005-11-24 Genencor International, Inc. Anti-cea scfv-beta-lactamase contructs (cab molecules) in adept
AU2005302459A1 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
ES2386367T3 (es) 2005-03-10 2012-08-17 Morphotek, Inc. Anticuerpos anti-mesotelina
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
US9150653B2 (en) * 2010-01-28 2015-10-06 Glaxo Group Limited CD127 binding proteins
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
KR102094022B1 (ko) 2013-04-29 2020-03-30 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP4021464A4 (en) * 2019-08-27 2024-01-03 The Trustees of The University of Pennsylvania SYNTHETIC CARS FOR TREATING IL13RA2-POSITIVE TUMORS IN HUMANS AND DOGS
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN112409485B (zh) * 2020-10-21 2022-10-25 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
BR9708910A (pt) * 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento

Also Published As

Publication number Publication date
JP2000510692A (ja) 2000-08-22
CZ353698A3 (cs) 1999-02-17
EP0896626A1 (en) 1999-02-17
NZ331978A (en) 2000-05-26
US6277599B1 (en) 2001-08-21
US20020142359A1 (en) 2002-10-03
ES2279539T3 (es) 2007-08-16
HUP9901562A2 (hu) 1999-08-30
WO1997042329A1 (en) 1997-11-13
TR199802227T2 (xx) 2000-07-21
SK150298A3 (en) 1999-04-13
NO985120L (no) 1998-12-29
AU719513B2 (en) 2000-05-11
DE69737188D1 (de) 2007-02-15
BR9708910A (pt) 1999-08-03
US6903203B2 (en) 2005-06-07
ATE350478T1 (de) 2007-01-15
NO985120D0 (no) 1998-11-03
AU2645597A (en) 1997-11-26
CN1217750A (zh) 1999-05-26
DE69737188T2 (de) 2007-10-11
IL126772A0 (en) 1999-08-17
PL329871A1 (en) 1999-04-12
CA2250579A1 (en) 1997-11-13
EP0896626B1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
HUP9901562A3 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
ZA966776B (en) Device in inhalers.
HUP9904177A3 (en) Antibody against human parathormone related peptides
ZA9710409B (en) Stable lyophilised pharmaceutical preparations comprising mono- or polyclonal antibodies
EP1032421A4 (en) NATURAL HUMAN MONOCLONAL ANTIBODIES
PL330842A1 (en) Purified superficial sperm antigen, monoclonal antibody therefor and applications associated therewith
EP0805161A4 (en) PROTEIN BINDING (1-3) -BETA-D-GLUCANE, PROTEIN RECOGNIZING ANTIBODIES AND USE OF PROTEIN AND ANTIBODY
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
HUP9901908A3 (en) P16 expression constructs and their application in cancer therapy
HUP9903886A3 (en) Azacycloalcane derivatives, preparation thereof and their applications in therapy
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
GB2316467B (en) Pedal and stopper structure
GB9815423D0 (en) Assays, therapeutic methods and means
ATE186559T1 (de) Leukoindigo-präparationen in granulatform
GB2329491B (en) Collection and delivery system
PL338123A1 (en) 6-pyrrolydin-2-ylpyridines, their production and application in therapy
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
AU1135595A (en) Saccharomyces-specific antigens and antibodies, their preparation and use
AU3728595A (en) Antibodies against an extracellular matrix complex and their use in the detection of cancer
AU4499196A (en) Antibodies for use in cancer therapy and diagnosis
GB9419256D0 (en) Antibody and conjugates
FR2735470B1 (fr) Nitrocetones et nitroximes, leur preparation et leur application en therapeutique
SE9503044D0 (sv) Antibodies for use in cancer therapy and diagnosis
EP0596725A3 (en) Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof.